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Abstract
Purpose: Optimal management of breast ductal carcinoma in situ (DCIS) is controversial, and many patients are still
overtreated. The local death of myoepithelial cells (MECs) is believed to be a pre-requisite to tumor invasion. We thus
hypothesized that loss of CD10 expression, a MEC surface peptidase, would signify basement membrane disruption and
confer increased risk of relapse in DCIS. The aim of our study was to retrospectively evaluate the prognostic value of CD10 in
DCIS.
Experimental Design: CD10 expression was evaluated by quantitative RT-PCR and immunohistochemistry using paraffin-
embedded samples of normal breast tissue (n=11); of morphologically normal ducts associated with DCIS (n=10); and of
DCIS without an invasive component (n=154).
Results: CD10 immunostaining was only observed in MECs in normal tissue and in DCIS. Normal tissue showed high mRNA
expression levels of CD10, whereas DCIS showed a variable range. After a median follow-up of 6 years, DCIS with CD10
expression below the levels observed in normal tissue (71%) demonstrated a higher risk of local relapse (HR=1.88;
[95CI:1.30–2.70], p=0.001) in univariate analysis. No relapse was observed in patients expressing high CD10 mRNA levels
(29%) similar to the ones observed in normal tissue. In multivariate analysis including known prognostic factors, low CD10
mRNA expression remained significant (HR=2.25; [95%CI:1.24–4.09], p=0.008), as did the recently revised Van Nuys
Prognostic Index (VNPI) score (HR=2.03; [95%CI:1.23–3.35], p=0.006).
Conclusion: The decrease of CD10 expression in MECs is associated with a higher risk of relapse in DCIS; this knowledge has
the potential to improve DCIS management.
Citation: Toussaint J, Durbecq V, Altintas S, Doriath V, Rouas G, et al. (2010) Low CD10 mRNA Expression Identifies High-Risk Ductal Carcinoma In Situ (DCIS). PLoS
ONE 5(8): e12100. doi:10.1371/journal.pone.0012100
Editor: Marc Vooijs, University Medical Center Utrecht, Netherlands
Received February 22, 2010; Accepted July 12, 2010; Published August 10, 2010
Copyright:  2010 Toussaint et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The Breast Cancer Research Foundation (BCRF - http://www.cancer.be/), the Swiss MEDIC Foundation, the Fonds National de la Recherche Scientifique
(FNRS - http://www2.frs-fnrs.be/) have supported the work. Jerome Toussaint was supported by a grant from the FNRS (FRIA). The funders had no role in study
design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: christos.sotiriou@bordet.be
. These authors contributed equally to this work.
Introduction
With the widespread use of high quality screening mammogra-
phy, the incidence of ductal carcinoma in situ (DCIS) has increased
dramatically. DCIS now accounts for approximately 20% of all
screening-detected breast cancer [1]. DCIS is pathologically
described as the proliferation of malignant epithelial cells that have
not invaded beyond the basement membrane. In reality, DCIS is a
heterogeneous group of pre-invasive breast cancers with various
patterns of morphology, expansion, and malignant potential.
The long-term prognosis of DCIS is excellent, with an expected
overall 10-year survival rate that exceeds 95%, even in the absence
of treatment [2]. However, 16% to 22% of women experience
local relapse within 10 years following lumpectomy alone, and
approximately one-half of these relapses are invasive breast
cancer. Adjuvant radiotherapy reduces the 10-year risk of relapse
to 7% to 9%, although it is associated with cutaneous toxicity and
a small long-term risk of secondary neoplasms [3–5].
The Van Nuys Prognostic Index (VNPI) is a useful tool to
evaluate the risk of local relapse. In the original VPNI [6] three
independent histo-pathological parameters of relapse were con-
sidered: tumor size, margin width and pathological grade.
Recently, the VNPI was revised to include the age of the patient
at diagnosis [7–9]. The VNPI score is divided into three risk
groups: low, intermediate and high. For low VPNI risk,
lumpectomy alone is recommended, while patients with interme-
diate VPNI risk are strongly recommended to receive adjuvant
radiotherapy following lumpectomy, and high-risk patients are
advised to undergo mastectomy. However, many patients in the
intermediate and high-risk categories would not relapse with
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or mastectomy. Therefore, additional prognostic biomarkers are
needed to improve decision-making following resection of DCIS.
There is growing evidence that alterations in the tumor
microenvironment might underlie local relapse in DCIS. Myo-
epithelial cells (MECs) that surround mammary ducts and lobular
acini are involved in mammary gland homeostasis and prevent
breast cancer progression. MECs maintain the basement mem-
brane, forming a physical barrier between epithelial cells and the
surrounding stroma, which blocks tumor cell invasion. MECs also
secrete paracrine mediators that inhibit tumor growth, invasion
and angiogenesis [10–12]. Two hypotheses (models) should
explain the transition from in situ to invasive carcinoma: the
‘‘escape’’ and the ‘‘release’’ models. In the escape model, the
tumor epithelial cells disrupt the MEC layer, degrade the
basement membrane, and migrate into the stroma, whereas in
the ‘‘release’’ model, the MECs disappear and the basement
membrane is disrupted at sites coinciding with areas of leukocytic
infiltration and accumulation of myofibroblasts [11,13].
CD10/CALLA is a surface biomarker of MECs expressed
during breast maturation. The expression of CD10 is decreased in
DCIS and completely lost in invasive breast cancer [14]. We
hypothesized that within the spectrum of DCIS, there is a
continuum in CD10 expression, with lower values of CD10
expression reflecting loss of integrity of the basement membrane
and, accordingly, an increased risk of local relapse. The aim of the
present study was to retrospectively evaluate CD10 expression in
DCIS tumors and to determine its association with long-term
disease free survival (DFS).
Materials and Methods
The present study adopted the REMARK guidelines for tumor
markers prognostic evaluation [15].
Patients and Sample Collection
The tissue samples used in this study were obtained from the
Jules Bordet Institute (Brussels) and Antwerp University Hospital
and approved for secondary use by the institutions’ respective
ethical committees, in compliance with the Belgian law of 19
December 2008 on human corporal material.
The expression levels of CD10 were assessed on a set of 11
normal breast tissue samples (median age of 52.3 years) obtained
from reduction mammaplasty and used to define a cut-off for high
expression of CD 10. The cut-off was corroborated with a set of 10
morphologically normal ducts associated with DCIS (median age
of 53.0 years). Both of these tissue sets were obtained from Jules
Bordet Institute.
The prognostic value of the CD10 marker was investigated in a
consecutive series of 154 paraffin-embedded (FFPE) samples from
patients treated surgically (lumpectomy or mastectomy) for ductal
carcinoma in situ (DCIS) at the Jules Bordet Institute (n=66; median
age of 53.5 years), and at Antwerp University Hospital (n=88;
median age of 54 years). Patients with adjacent invasive carcinoma
(invasion .=1mm in the stroma surrounding the ducts) were
excluded. 58% of low VPNI risk patients were treated by
lumpectomy alone; 41% of intermediate VPNI risk patients received
adjuvant radiotherapy following lumpectomy; and 81% of high-risk
patients underwent mastectomy. Only 6 patients received tamoxifen
treatment. The patient characteristics are described in table 1.
Updated VNPI 2003 assessment [16]
Tumor size, margin width, nuclear tumor grade (low grade
versus high grade) and presence of comedo-necrosis were centrally
reviewed for all patients by a single breast-experienced pathologist
(DL), blinded to CD10 expression and long-term outcome. Patient
age at diagnosis was included, according to the updated VNPI
calculation requirements.
Assessment of CD10 expression pattern by IHC
The pattern of CD10 expression was assessed by immuno-
histochemistry (IHC) on FFPE slides using the standard immuno-
peroxidase method with an automated DAKO immunostainer
(monoclonal CD10, clone 56C6, Novocastra, UK; dilution 1:50,
antigen retrieval in Decloak 5 min in TRS). Each immunohisto-
chemical CD10 analysis was defined as a score combining the
expression and intensity values (range from 2 to 6). CD10
expression was reported on a scale of 1 to 3 as focal ([1] 10% of
duct circumference), partial ([2] 10%–90% of duct circumference),
or circumferential ([3] .90% of duct circumference). The staining
intensity was evaluated on a scale of 1 to 3, with 1 designated as
weak staining, 2 as intermediate, and 3 as intense.
Quantification of CD10 expression by qRT-PCR
Haematoxilin-eosin slides were also reviewed by a single breast-
experienced pathologist (DL) charged with the task of circling the
DCIS portion of the slide for tumor cell enrichment using TMA
technology. RNA from FFPE samples was extracted from 8 punch
biopsies (0.6 mm diameter and 2 mm sections) using the
MasterPure
TM Purification kit (Epicentre, Madison, WI) after
paraffin removal with xylene. A DNase 1 treatment step was
included. RNA was quantified using the NanoDropH ND-1000
UV-Vis Spectrophotometer (NanoDrop Technologies, Wilming-
ton, DE).
Reverse transcription (RT) was performed using a Super-
Script
TMFirst-Strand Synthesis kit for qRT-PCR (Invitrogen
Corp., Carlsbad, CA). Total RNA (300 ng) was reverse tran-
scribed in a final volume of 21 ml with 50 ng of random hexamers.
An RNase H treatment step was included.
Quantitative PCR reactions were performed in 96-well plates
using Applied Biosystems ABI PrismH 7900HT (TaqManH instru-
ments). Gene expression was measured in duplicate using 5ng
equivalentcDNAper reaction well. Amplificationswereperformed in
25 ml PCR mixture containing 300nM of each primer and 12,5 ml
26 SYBRH Green PCR Master Mix (Applied Biosystems). After
2m i na t5 0 uC and 10 min at 95uC,cDNA was subjected to 40 cycles
of PCR, with a denaturation step at 95uC for 30 sec followed by a
combined annealing/extension step at 60uCf o r1m i n .
CD10 (NM_007289) forward primer (TGGGTTCTTGAAG-
GACATCTTTC) and reverse primer (CGTTACGGCAACTTT-
GACATTTT) were designed using the Primer ExpressH software
(PE Applied Biosystems). Four housekeeper genes were selected on
the basis of the literature as reference genes for data normalization
(TFRC, GUS, RPLPO and TBP) (Table 2).
Data analysis
qRT-PCR data normalization: the average value of the
expression of housekeeper genes was used as reference, and a
threshold cycle (Ct) value was defined for each sample by taking off
this average
CD10expression~CD10Ct{
1
4
X 4
i~1
Gref ðÞ
where CD10expression is the CD10 threshold cycle and Gref is the
sum of the four housekeeper genes (TBP, RPLPo, GUS, TFRC).
CD10: DCIS Prognostic Marker
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normal breast samples were considered as CD10 low-expressing
samples.
Survival analysis
Disease free survival (DFS) was defined as either locoregional
relapse of DCIS and/or the presence of invasive breast carcinoma.
Non-breast cancer primaries and non-breast cancer deaths were
considered as non-events. Survival curves were computed using
the Kaplan-Meier product limit estimator. Hazard ratios for
continuous and discrete variables were estimated through Cox’s
proportional hazard regression models.
Two-tailed p-values are reported, and p-values,0.05 were
considered statistically significant. All statistical analyses were
carried out using R version 2.5.1 and SPSS version 15 (SPSS Inc.
1999, Chicago, IL).
Results
Pattern of CD10 expression in normal breast tissue and
DCIS
In normal breast tissue (n=11) and availableDCIS tissue from the
Jules Bordet Institute (n=62/88), CD10 protein expression was
exclusively localized on the MECs. Strong homogeneous membrane
Table 1.
Bordet DCIS pop (N=66) Antwerp DCIS pop (N=88) P-val.*
Patient and tumor characteristics
Age at diagnosis (years)
.60
40–60
,40
UK
23
39
4
/
28
52
8
/
0.601
Menopausal status
Premenopausal
Perimenopausal
Postmenopausal
UK
23
36
7
21
7
42
18
0.533
Disease-free survival (years)
(range)
6.95
(0.25–14)
5.32
(0.5–21)
0.124
Event
Yes
No
10
56
10
78
0.823
Tumor size (mm)
#15
16–40
$40
UK
23
17
15
11
39
29
20
/
0.726
Margin width (mm)
$ 10
1–9
,1
UK
10
10
31
15
15
25
48
/
0.558
Pathological class
1
2
3
UK
3
5
58
/
29
22
35
2
3.7E-09
Comedo necrosis
Present
Absent
UK
19
42
5
51
35
2
0.238
Estrogen receptor status
Positive
Negative
UK
/6 2
16
10
/
VNPI risk score
Low (4–6)
Intermediate (7–9)
High (10–12)
UK
1
25
19
21
21
49
18
/
3.8E-04
Treatment
Lumpectomy
Lumpectomy + Radiation
Mastectomy
UK
VNPI : UK
8
0
13
Low
1
0
0
/
Inter
9
8
8
/
High
3
1
15
/
Low
10
5
3
3
Inter
11
18
10
10
High
1
2
15
0
0.470
Legend: UK=Unknown; * Wilcoxon (Mann-Whitney U-test.
doi:10.1371/journal.pone.0012100.t001
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was observed in all normal breast samples (figure 1.A). In contrast,
DCIS showed a variable range of CD10 immunostaining. High
CD10 immunostaining (score=6), similar to that observed in the
normal breast tissue, was present in 27% (17/62) of the DCIS
samples, whereas 73% (45/62) showed CD10 immunostaining below
thelevelsobserved inthenormaltissue(score,6)(figure1.Band1.C).
Quantification of CD10 expression by qRT-PCR
CD10 mRNA level was quantified by qRT-PCR on FFPE
samples from normal breast tissue (n=11), normal breast
associated with DCIS (n=10) and DCIS samples (N=154). A
high CD10 mRNA level was reported for all normal breast tissue
(n=21) as well as 29% of the DCIS (figure 2.A), representing a
proportion consistent with the one for CD10 immunostaining.
DCIS samples were divided in two groups based on CD10 mRNA
level: one group whose expression level was lower than that of the
normal breast tissues (low CD10-expressing subgroup), and one
group whose expression was similar to that of the normal samples
(high CD10-expressing subgroup).
There was a significant but weak correlation between CD10
expression measured by IHC and qRT-PCR (r=0.35, p=5E-03).
When both technologies were compared, CD10 status was
discordant in 32% of the cases.
CD10 expression and clinical outcome
CD10 mRNA expression was associated with long-term
outcome in the 154 pure DCIS samples. Twenty (13%) loco-
regional relapses (in situ or invasive) were documented after a
median follow-up of 6years (range 0.25 to 21.1 years).
Low CD10 mRNA expression was statistically associated with
increased risk of relapse (HR=1.88; [95CI: 1.30–2.70], p=0.001)
when CD10 was considered as a continuous variable. Similar
results were seen when DCIS patients were divided into low and
high CD10 expressing subgroups (p=4.7E-04). None of the 44
patients with high CD10 mRNA experienced a relapse (figure 2.B).
The DFS at 10 years for the high CD10 group was 100% versus
63% for the low CD10 group. No prognostic value was found
when CD10 expression was measured by IHC (log rank test
p=0.73; HR=1.46; [95CI: 0.93–2.30], p=9.5E-02).
Because patient treatment was heterogeneous (lumpectomy,
lumpectomy and radiotherapy, mastectomy), we analyzed the
association between the expression of CD10 and clinical outcome
in each treatment subgroup separately. Low CD10 expression was
associated with a 24%, 18.5% and 14% rate of relapse in the
Table 2. Forward and reverse primers sequences for
signature and normalization genes.
Gene Name
Accession
number Primer sequence
Genes of Normalization
GUS NM_000181 -GAGTGGTGCTGAGGATTGGC
-TCTAGCGTGTCGACCCCATT
TBP NM_003194 -GCCCGAAACGCCGAATAT
-TCGTGGCTCTCTTATCCTCATGA
RPLP0 NM_001002 -ACCAAGGAGGACCTCACTGAG
-ACCAGCACGGGCAGCAG
TFRC NM_003234 -GGAGCCAGGAGAGGACTTCC
-TTCTCCGACAACTTTCTCTTCAGG
doi:10.1371/journal.pone.0012100.t002
Figure 1. CD10 immunostaining of the myoepithelial cell (MECs) layer (original magnification 6200). (A) intense staining (3) and a
circumferential membrane expression (3) observed on normal breast (score=6); (B) intense staining (3) and a circumferential membrane expression
(3) observed on DCIS (score=6); (C) intermediate staining (2) and partial membrane expression (2) observed on DCIS (score=4); (D) weak staining (1)
and focal membrane expression (1) observed on DCIS (score=2).
doi:10.1371/journal.pone.0012100.g001
CD10: DCIS Prognostic Marker
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radiotherapy and mastectomy, respectively. In the groups of
patients treated by lumpectomy or lumpectomy plus radiotherapy,
none of the patients with high CD10 mRNA (N=17/77)
experienced a relapse (p=1.6E-02) (figure 2.C). The DFS at 10
years for the high CD10 group was 100%, as compared to 41% for
the low CD10 group.
VNPI and clinical outcome
Since the revised VNPI is considered to be a useful tool to
predict local relapse in DCIS, we sought to investigate its
prognostic performance in our population. The VNPI score was
available for 86% (133/154) of the patients in this study: 16.5%
(22/133) were low VNPI risk, 55.5% (74/133) were intermediate
VNPI risk, and 28% (37/133) were high VNPI risk. The observed
10-year DFS was 100% for the low VPNI risk group, 64% for the
intermediate VPNI risk group, and 84% for the high VNPI risk
group (figure 3).
Combined CD10 and VPNI risk
We evaluated the prognostic outcome according to combined
VPNI and CD10 risk. Seventeen of the 22 patients (77%)
considered as low VNPI risk had high CD10 risk (CD10 mRNA
low), whereas 33 of the 38 patients (87%) with high CD10 mRNA
expression (low CD10 risk) were considered intermediate or high
VNPI risk (figure 4.A). A greater proportion of patients were
considered low risk based upon CD10 expression (CD10 mRNA
high) (28.5%, 38/133) when compared to VNPI (16.5%, 22/133).
By combining both criteria, 41% (55/133) of the patients were
reclassified as low risk group (figure 4.B). Of interest, none of those
patients experienced a relapse (p=1.6E-02).
A multivariate analysis demonstrated that both CD10 and
VNPI were the only independent prognostic factors
(HRCD10=2.39; [95%CI: 1.52–3.76], p=0.0001; HRVNPI=1.39;
[95%CI: 1.01–1.94], p=0.05) when selecting CD10 mRNA level,
VNPI score, treatments and menopausal status.
Discussion
In our study, CD10 protein expression by IHC was located
exclusively on the MECs in normal breast and in one-third of the
DCIS, reflecting a well-organized MEC layer and a proportion
between the one reported by Kalof et al. [14] and Hilson et al. [17].
However, in two-thirds of the DCIS samples lower CD10 expression
was observed, suggesting an alteration of the MEC layer, which
totally disappears in invasive breast cancer [14]. In some cases of
invasive breast cancer, CD10 expression has been reported in the
fibroblasts and associated with a bad prognosis, but this is a biological
process independent from the one observed in this study.
CD10 mRNA expression was retrospectively evaluated using
qRT-PCR, and its prognostic performance was assessed in a
population of 154 DCIS paraffin-embedded samples. CD10
mRNA was expressed in all normal breast tissue and one-third
of the DCIS patients, a proportion in the same range as our
findings for IHC. Of clinical relevance, no relapse occurred in the
group of DCIS patients with high CD10 expression. In contrast,
low CD10 mRNA expression was significantly associated with an
increased risk of relapse following resection of DCIS. A similar
trend was found in the subgroup of patients treated with
mastectomy alone. These findings support the notion that the
progression of DCIS to invasive cancer may be due, in part, to
MEC abnormalities that result in a loss of their normal tumor
suppressor functions. Allinen et al. [18] reported that when
compared with normal MECs, DCIS-associated MECs show
down-regulation of a variety of genes involved in normal functions,
including those for oxytocin receptor, laminin and thrombospon-
din, and up-regulation of genes for chemokines that enhance
epithelial cell proliferation, migration, invasion and stromal
Figure 2. CD10 expression and clinical outcome. (A) scatter plot
of CD10 expression evaluated by qRT-PCR for normal (N=11) and DCIS
(N=154) samples. All normal samples and one-third of the DCIS were
considered CD10 positive. (B) Kaplan-Meier curves of disease-free
survival for patients with DCIS (N=154) according to CD10 mRNA
expression by qRT-PCR expression. (C) Kaplan-Meier curves of disease-
free survival for patients with DCIS treated by tumorectomy only or
tumorectomy and radiation (N=77) according to CD10 mRNA
expression by qRT-PCR expression.
doi:10.1371/journal.pone.0012100.g002
CD10: DCIS Prognostic Marker
PLoS ONE | www.plosone.org 5 August 2010 | Volume 5 | Issue 8 | e12100angiogenesis, such as SDF1/CXCL12 and CXCL14. DCIS-
associated MECs also showed increased levels of enzymes involved
in the degradation of the extracellular matrix, such as matrix
metalloproteinases, which might be responsible for local invasion.
In our cohort, the VNPI – considered a useful prognostic
marker for treatment decision making in DCIS – could potentially
avoid overtreatment in 16% of the DCIS patients; using CD10,
this figure reached 28.5%. With respect to clinical relevance, both
VNPI and CD10 were independent prognostic indicators of
relapse. However, by combining both predictors we were able to
identify a group of patients representing up to 41% of the DCIS
patient population with no relapse at 10 years of follow up. All the
Figure 3. VNPI and clinical outcome: Disease-free survival analysis for patients with DCIS (N=133) according to VNPI risk group.
doi:10.1371/journal.pone.0012100.g003
Figure 4. Combined CD10 and VPNI risk. (A) Cross-tabulation between CD10 qRT-PCR expression and VNPI score. (B) Disease-free survival
analysis for patients with DCIS according to CD10 mRNA expression by qRT-PCR combined with VNPI risk group.
doi:10.1371/journal.pone.0012100.g004
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groups: either a group with high VNPI scores representative of
high tumor stage, or one with low CD10 expression reflecting at
least some MEC layer alterations. Both characteristics – tumor
stage and low CD10 expression – seem to be necessary for
predicting relapse, which highlights the importance of assessing
intrinsic DCIS properties as well as the surrounding microenvi-
ronment.
Conclusion
Decreased expression of CD10 in DCIS is associated with a
higher risk of local relapse. These promising results are currently
being validated in a larger patient series. It is hoped that
assessment of CD10 combined with VPNI may lead to improved
treatment tailoring for women with DCIS in the future.
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